Bluebird Bio Impresses Yet Again With Gene Therapy Platform – Seeking Alpha
Seeking Alpha |
Bluebird Bio Impresses Yet Again With Gene Therapy Platform
Seeking Alpha Bluebird Bio posts positive phase 1/2 data for its Lentiglobin therapy in beta Thalassemia in the New England Journal Of Medicine Publication. One dose of treatment with Lentiglobin in the phase 1/2 study was able to cause a majority of the patients to … |
